IV to Oral Switch Policy
Indications for IV Route |
1. Sepsis or severe sepsis 2. Febrile with neutropenia or immunosuppression 3. Specific infection indications e.g. Endocarditis, Meningitis, deep abscesses, Staph aureus bacteraemia 4. Oral route compromised, nil by mouth, reduced absorption, mechanical swallowing disorder, unconscious, no oral formulation available |
Definition of Sepsis |
Life threatening organ dysfunction caused by a dysregulated host response to a new infection – IV therapy should be commenced immediately and reviewed on a daily basis as patient improves. Severity of illness may be guided by NEWS. |
IV to Oral Switch Policy |
|
Patients receiving IV therapy MUST be reviewed for a switch to oral WITHIN THE FIRST 72 HOURS then EVERY 24 HOURS THEREAFTER if the indications listed above are not present and the patient is improving. If IV therapy is still required, de-escalate if possible based on microbiology results. Reason for continuing IV therapy MUST be documented at reach review unless suspected/confirmed diagnosis advocating prolonged IV treatment. |
|
General features indicating oral antibiotics are appropriate:
AND there is an oral formulation or alternative antibiotic available should be switched to oral |
|
IV Agent/Empirical Regime |
Oral Agent |
Amoxicillin Clarithromycin Co-amoxiclav Flucloxacillin Benzylpenicillin Metronidazole Ciprofloxacin 400mg bd Ciprofloxacin 400mg tds Levofloxacin Clindamycin Piperacillin/Tazobactam
Meropenem
Amoxicillin+Gentamicin+Metronidazole Vancomycin+Gentamicin+Metronidazole |
Amoxicillin 500mg – 1g TDS Clarithromycin 500mg BD Co-amoxiclav 625mg TDS Flucloxacillin 500mg-1g QDS Amoxicillin 500mg - 1g TDS Metronidazole 400mg TDS Ciprofloxacin 500mg BD Ciprofloxacin 750mg BD Levofloxacin 500mg BD Clindamycin 300mg-450mg QDS Co-amoxiclav 625mg 8 hourly (if prior co-amoxiclav use - Co-trimoxazole 960mg 12 hourly AND Metronidazole 400mg PO 8 hourly)
d/w microbiology
Co-amoxiclav 625mg 8 hourly Co-trimoxazole 960mg 12 hourly AND Metronidazole 400mg PO 8 hourly
|
Remember CIPROFLOXACIN, METRONIDAZOLE, CLINDAMYCIN and CLARITHROMYCIN have excellent oral bioavailability so oral is as effective as IV |
Potential benefits from IV switch
- Earlier mobilisation and potential discharge of patient
- Reduced risk of infection from vascular access devices (e.g. thrombophlebitis, Staph auerus bacteraemia)
- Reduction in non-infectious adverse events associated with IV access (e.g. extravasation, pain)
- Freeing up of nursing time to manage other aspects of patient care
- Improved use of resources